The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Ascend Laboratories would like to inform you of a product recall involving Minocycline Hydrochloride Extended-Release (ER) Tablets USP, 115 mg.

An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis for long-term stability testing (LT conditions: 25 ± 2 °C / 60 ± 5 % RH) of Minocycline Hydrochloride Extended-Release Tablets USP, 115 mg, for batch number 25141635.

Minocycline HCl ER tablets is a tetracycline class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. Further, the drug is not indicated for use in the last half of pregnancy, infancy and childhood up to the age of 8 years. Dissolution results up to 6 months are well within the specification limits. Results of Assay, CU and impurity testing are well within the specification limits. Hence, there risk to the patient with respect to safety of the medication is negligible.

Our firm began shipping this product on September 5, 2025.

PRODUCT: Minocycline Hydrochloride Extended-Release (ER) Tablets USP, 115 mg, 30 count

NDC NUMBER: 67877-644-30

LOT NUMBER: 25141635

EXPIRY DATE: 4/30/2028

INITIAL DISTRIBUTION DATE: 9/5/2025